MA45997A - Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d - Google Patents

Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d

Info

Publication number
MA45997A
MA45997A MA045997A MA45997A MA45997A MA 45997 A MA45997 A MA 45997A MA 045997 A MA045997 A MA 045997A MA 45997 A MA45997 A MA 45997A MA 45997 A MA45997 A MA 45997A
Authority
MA
Morocco
Prior art keywords
disease
methods
treating crohn
nkg2d antibody
nkg2d
Prior art date
Application number
MA045997A
Other languages
English (en)
French (fr)
Inventor
Carrie Brodmerkel
Mark Curran
Linda Greenbaum
Shannon Telesco
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA45997A publication Critical patent/MA45997A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA045997A 2016-08-19 2017-08-17 Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d MA45997A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662377358P 2016-08-19 2016-08-19

Publications (1)

Publication Number Publication Date
MA45997A true MA45997A (fr) 2019-06-26

Family

ID=61197073

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045997A MA45997A (fr) 2016-08-19 2017-08-17 Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d

Country Status (9)

Country Link
US (1) US20190292265A1 (enExample)
EP (1) EP3500293A4 (enExample)
JP (1) JP2019528285A (enExample)
KR (1) KR20190038919A (enExample)
AU (1) AU2017312049A1 (enExample)
CA (1) CA3034324A1 (enExample)
MA (1) MA45997A (enExample)
MX (1) MX2019001958A (enExample)
WO (1) WO2018035330A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
EP3797120A1 (en) 2018-05-21 2021-03-31 Compass Therapeutics LLC Compositions and methods for enhancing the killing of target cells by nk cells
CA3105464A1 (en) 2018-07-06 2020-01-09 Cedars-Sinai Medical Center Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures
AU2019408408A1 (en) 2018-12-21 2021-06-03 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
TW202515610A (zh) * 2019-04-22 2025-04-16 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
CN112578124A (zh) * 2019-09-27 2021-03-30 廖睿 检测粪钙卫蛋白含量的试剂在制备输卵管病变筛查试剂盒中的用途
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
CN116199777B (zh) * 2021-12-01 2025-01-28 北京免疫方舟医药科技有限公司 抗hNKG2D抗体及其应用
EP4448761A1 (en) 2021-12-16 2024-10-23 Valerio Therapeutics New conjugated nucleic acid molecules and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266432A1 (en) * 2004-02-26 2005-12-01 Illumina, Inc. Haplotype markers for diagnosing susceptibility to immunological conditions
RU2563343C2 (ru) * 2007-12-14 2015-09-20 Ново Нордиск А/С Антитела к человеческому nkg2d и их применения
RS54707B1 (sr) * 2009-07-30 2016-08-31 Teva Pharmaceutical Industries Ltd. Tretman kronove bolesti lakvinimodom
WO2011082382A2 (en) * 2009-12-31 2011-07-07 The Trustees Of Columbia University In The City Of New York Methods for detecting and regulating alopecia areata and gene cohorts thereof
RU2017129455A (ru) * 2015-01-26 2019-03-04 Селлектис Сконструированные иммунные клетки с нокаутом рецептора т-клеток, снабженные химерными антигенными рецепторами, связывающимися с cd123, для лечения рецедивирующего/устойчивого острого миелоидного лейкоза или новообразования из бластных плазмоцитоидных дендритных клеток

Also Published As

Publication number Publication date
WO2018035330A1 (en) 2018-02-22
JP2019528285A (ja) 2019-10-10
US20190292265A1 (en) 2019-09-26
EP3500293A1 (en) 2019-06-26
EP3500293A4 (en) 2020-08-19
MX2019001958A (es) 2019-06-13
KR20190038919A (ko) 2019-04-09
AU2017312049A1 (en) 2019-02-21
CA3034324A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
MA45997A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d
EP3762015A4 (en) METHOD OF TREATMENT OF CROHN'S DISEASE WITH ANTI-IL23 SPECIFIC ANTIBODY
EP3645121A4 (en) METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS
MA51631A (fr) Anticorps anti-pd1 et méthodes de traitement
EP3490582A4 (en) METHOD AND COMPOSITIONS FOR TREATING MYELOFIBROSE
EP3452166A4 (en) INTRANASAL STIMULATION FOR THE TREATMENT OF DISEASES OF MEIBOM'S GLANDS AND BLEPHARITIS
EP3515505A4 (en) AAV TREATMENT BY MORBUS ALZHEIMER
MA51815A (fr) Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp
MA47206A (fr) Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
EP3644996A4 (en) METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS
EP3528852A4 (en) METHOD AND COMPOSITIONS FOR TREATING MORBUS FABRY
EP3752180A4 (en) METHOD OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES
EP3291815A4 (en) METHOD FOR TREATING A NEURODEEGENERATIVE DISEASE
MA52962A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
EP3402533A4 (en) METHOD AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE
MA47362A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
MA44510A (fr) Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23
EP3386520A4 (en) METHOD FOR THE TREATMENT OF EYE DISEASES OR DISORDERS
EP2978446A4 (en) METHOD AND MEANS FOR THE TREATMENT OF MORBUS ALZHEIMER
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
EP3393468A4 (en) METHOD FOR TREATING AN IMMUNE WEAKNESS
MA46842A (fr) Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8
HUE059387T2 (hu) Parkinson-kór kezelése
MA47395A (fr) Méthode pour le traitement d'une maladie neurologique